Publicacións en colaboración con investigadores/as de Clínica Universitaria de Navarra (43)

2023

  1. The New ERS/ATS 2022 Bronchodilator Response Recommendation: Comparison With the Previous Version in an Asthma Cohort

    Archivos de Bronconeumologia, Vol. 59, Núm. 9, pp. 608-611

2021

  1. Long-term prognosis of women with Brugada syndrome and electrophysiological study

    Heart Rhythm, Vol. 18, Núm. 5, pp. 664-671

2020

  1. Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis

    European journal of endocrinology, Vol. 182, Núm. 1, pp. 11-21

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

    British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807

  3. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

    Blood

2016

  1. Impact of cytomegalovirus infection on severe hepatitis c recurrence in patients undergoing liver transplantation

    Transplantation, Vol. 100, Núm. 3, pp. 593-599

  2. Risk of pacemaker implantation after uneventful successful cavotricuspid isthmus radiofrequency ablation in patients with common atrial flutter

    International Journal of Cardiology, Vol. 202, pp. 285-288

  3. SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1237-1242

2015

  1. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

    Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69

2014

  1. Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index

    International Journal of Endocrinology, Vol. 2014

  2. Clinical management guidelines for subarachnoid haemorrhage. Diagnosis and treatment

    Neurologia

  3. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

    The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111

  4. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial

    British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336

2013

  1. Dislipidemia en población diabé tica tratada con estatinas. Resultados del Dyslipidemia International Study en España

    Medicina Clinica, Vol. 141, Núm. 10, pp. 430-436

  2. Insuficiencia suprarrenal y su tratamiento sustitutivo. Su realidad en España

    Endocrinologia y Nutricion

2012

  1. Citicoline in the treatment of acute ischaemic stroke: An international, randomised, multicentre, placebo-controlled study (ICTUS trial)

    The Lancet, Vol. 380, Núm. 9839, pp. 349-357

2011

  1. Anticoagulation prescription in atrial fibrillation

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 10, pp. 1473-1479

  2. Immunoglobulin-E reactivity to wine glycoproteins in heavy drinkers

    Alcohol, Vol. 45, Núm. 2, pp. 113-122